Literature DB >> 15001273

Evaluation of novel modified tangential irradiation technique for breast cancer patients using dose-volume histograms.

Atsuya Takeda1, Naoyuki Shigematsu, Tadashi Ikeda, Osamu Kawaguchi, Shoji Kutsuki, Ryochi Ishibashi, Etsuo Kunieda, Toshiaki Takeda, Kazuhiko Takemasa, Hisao Ito, Takashi Uno, Hiromitsu Jinno, Atsushi Kubo.   

Abstract

PURPOSE: We have previously reported that entire axillary lymph node regions could be irradiated by the modified tangential irradiation technique (MTIT). In this study, MTIT was compared with a conventional irradiation technique (CTIT) using dose-volume histograms to verify how adequately MTIT covers the breast and axillary lymph node region and the extent to which it involves the lung and heart. METHODS AND MATERIALS: Forty-four patients with early-stage breast cancer were treated by lumpectomy, axillary dissection, and postoperative radiotherapy. Twenty-two patients were treated with MTIT and 22 with CTIT. In 25 patients, the breast tumor was on the left and in 19 on the right. During axillary dissection, surgical clips were left as markers at the border of the axillary lymph node region. MTIT was planned by setting the dorsal edge of the radiation field on a lateral-view simulator film at the dorsal edge of the humeral head and the cranial edge of the radiation field at the caudal edge of the humeral head. CTIT was planned to ensure radiation of the breast tissue without considering the axillary region. In this study, all patients underwent computed tomography, and the CT data were transmitted on-line to a radiotherapy planning system, in which the dose-distribution computed tomography images and dose-volume histograms were calculated by defining the breast, axillary region (levels I, II, and III), lung, and heart region.
RESULTS: Dose-volume histogram analysis demonstrated that breast tissue was radiated with an 86.5-100% volume (median 96.5%) by MTIT and an 83-100% volume (median, 95%) by CTIT at >95% of the isocenter dose. The axillary lymph node regions at Levels I, II, and III were irradiated with 84-100% (median, 94.5%), 59-100% (median, 89%), and 70-100% (median, 89.5%) volumes, respectively, by MTIT and with 2-84% (median, 38%), 0-53% (median, 15%), and 0-31% (median, 0%) volumes, respectively, by CTIT at >70% of the isocenter dose. The ipsilateral lung was irradiated with a 5-22% volume (median, 11.5%) by MTIT and 5-15% volume (median 9%) by CTIT at >90% of the isocenter dose. In all 25 left-sided breast cancer patients, the volumes irradiated with an 80% isocenter dose were <30 cm(3).
CONCLUSION: The results of our study demonstrated that the breast tissue was sufficiently irradiated with both CTIT and MTIT planning, the axillary lymph node areas irradiated by MTIT were much wider than those irradiated by CTIT at all levels, and the lung and heart volumes irradiated by MTIT were small.

Entities:  

Mesh:

Year:  2004        PMID: 15001273     DOI: 10.1016/j.ijrobp.2003.10.010

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

1.  Coverage of axillary lymph nodes with high tangential fields in breast radiotherapy.

Authors:  G Alço; S I Iğdem; T Ercan; M Dinçer; R Sentürk; S Atilla; F Oral Zengin; S Okkan
Journal:  Br J Radiol       Date:  2010-12       Impact factor: 3.039

2.  Virtual lymph node analysis to evaluate axillary lymph node coverage provided by tangential breast irradiation.

Authors:  Shin-Hyung Park; Jae-Chul Kim; Jeong Eun Lee; In-Kyu Park
Journal:  Radiat Oncol J       Date:  2015-03-31

Review 3.  Radiation therapy after breast-conserving surgery.

Authors:  Naoyuki Shigematsu; Atsuya Takeda; Naoko Sanuki; Junichi Fukada; Takashi Uno; Hisao Ito; Osamu Kawaguchi; Etsuo Kunieda; Atsushi Kubo
Journal:  Radiat Med       Date:  2006-06

4.  Axillary Irradiation with High Tangent Fields for Clinically Node-Negative Breast Cancer: Can 3-D Conformal Radiotherapy with a Field-in-Field Technique Better Control the Axilla?

Authors:  Naoko Sanuki; Atsuya Takeda; Atsushi Amemiya; Toru Ofuchi; Masato Ono; Haruki Ogata; Ryo Yamagami; Jun Hatayama; Takahisa Eriguchi; Etsuo Kunieda
Journal:  Breast Care (Basel)       Date:  2013-10       Impact factor: 2.860

5.  Complication rates in patients with negative axillary nodes 10 years after local breast radiotherapy after either sentinel lymph node dissection or axillary clearance.

Authors:  A Gabriella Wernicke; Michael Shamis; Kulbir K Sidhu; Bruce C Turner; Yevgenyia Goltser; Imraan Khan; Paul J Christos; Lydia T Komarnicky-Kocher
Journal:  Am J Clin Oncol       Date:  2013-02       Impact factor: 2.339

6.  A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance.

Authors:  A Gabriella Wernicke; Robert L Goodman; Bruce C Turner; Lydia T Komarnicky; Walter J Curran; Paul J Christos; Imraan Khan; Katherine Vandris; Bhupesh Parashar; Dattatreyudu Nori; K S Clifford Chao
Journal:  Breast Cancer Res Treat       Date:  2010-09-19       Impact factor: 4.872

7.  Tangential vs. defined radiotherapy in early breast cancer treatment without axillary lymph node dissection: a comparative study.

Authors:  Mirko Nitsche; Nils Temme; Manuela Förster; Michael Reible; Robert Michael Hermann
Journal:  Strahlenther Onkol       Date:  2014-05-17       Impact factor: 3.621

8.  Axillary lymph node dose with tangential whole breast radiation in the prone versus supine position: a dosimetric study.

Authors:  Kara Lynne Leonard; David Solomon; Jaroslaw T Hepel; Jessica R Hiatt; David E Wazer; Thomas A DiPetrillo
Journal:  Radiat Oncol       Date:  2012-05-18       Impact factor: 3.481

9.  A Radiation Oncologist's Guide to Axillary Management in Breast Cancer: A Walk Through the Trials.

Authors:  Julie K Jang; Elana R Sverdlik; Naomi R Schechter
Journal:  Curr Breast Cancer Rep       Date:  2019-09-14

10.  Research on different techniques in breast cancer radiotherapy.

Authors:  Mehmet Hakan Dogan; Seyit Burhanedtin Zincircioglu; Mahmut Aydinol
Journal:  Contemp Oncol (Pozn)       Date:  2013-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.